Drug Treatment of Certain Chronic Autoimmune Disorders Including Acute Exacerbations of Ms and Ra

Purified Cortrophin Gel

Payments companies reported to CMS as associated with Purified Cortrophin Gel. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.2Massociated payments (2023-2025)
15,528clinicians with associated payments
1company reporting

By year

2023 $832K
2024 $1.1M
2025 $2.3M

Payments reported as associated with Purified Cortrophin Gel, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Rheumatology $1.1M
Ophthalmology $540K
Nephrology (Internal Medicine) $537K
Neurology (Psychiatry & Neurology) $372K
Pulmonary Disease $330K
Family $249K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Purified Cortrophin Gel

These are the largest totals companies reported as associated with Purified Cortrophin Gel. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Sudhakar Tumuluri San Francisco, CA Rheumatology $187,035.05
Dhiman Basu Colleyville, TX Rheumatology $117,028.82
Wassim Saikali Beckley, WV Rheumatology $90,234.88
Francis Mah Pittsburgh, PA $78,886.70
Rajkumar Dasgupta Pasadena, CA Pulmonary Disease $67,561.24
Jessica Coleman Beaufort, SC Nephrology (Internal Medicine) $65,449.65
Sanjay Kedhar New York, NY Uveitis and Ocular Inflammatory Disease $64,359.56
Regina Berkovich West Hollywood, CA Neurology (Psychiatry & Neurology) $63,045.86
Kostas Botsoglou Cheektowaga, NY Rheumatology $62,646.52
Andrew Sulich Saint Clair Shores, MI Rheumatology $61,237.73

Prescribed Purified Cortrophin Gel?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.